These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1025 related items for PubMed ID: 31027892

  • 21. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.
    Transplantation; 2020 Jan; 104(1):154-164. PubMed ID: 30893292
    [Abstract] [Full Text] [Related]

  • 22. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
    Watarai Y, Danguilan R, Casasola C, Chang SS, Ruangkanchanasetr P, Kee T, Wong HS, Kenmochi T, Amante AJ, Shu KH, Ingsathit A, Bernhardt P, Hernandez-Gutierrez MP, Han DJ, Kim MS.
    Clin Transplant; 2021 Oct; 35(10):e14415. PubMed ID: 34216395
    [Abstract] [Full Text] [Related]

  • 23. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B, Schemmer P, Braun F, Dworak M, Wimmer P, Schlitt H.
    Trials; 2015 Mar 26; 16():118. PubMed ID: 25873064
    [Abstract] [Full Text] [Related]

  • 24. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.
    De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, Jonas S, Sudan D, Fung J, Fischer L, Duvoux C, Chavin KD, Koneru B, Huang MA, Chapman WC, Foltys D, Witte S, Jiang H, Hexham JM, Junge G, H2304 Study Group.
    Am J Transplant; 2012 Nov 26; 12(11):3008-20. PubMed ID: 22882750
    [Abstract] [Full Text] [Related]

  • 25. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
    Cruzado JM, Pascual J, Sánchez-Fructuoso A, Serón D, Díaz JM, Rengel M, Oppenheimer F, Hernández D, Paravisini A, Saval N, Morales JM, Evita Study Group.
    Transpl Int; 2016 Dec 26; 29(12):1317-1328. PubMed ID: 27648523
    [Abstract] [Full Text] [Related]

  • 26. Renal Function Changes Under Everolimus Plus Cyclosporine or Everolimus Plus Tacrolimus After Heart Transplantation.
    Chiang TY, Tsao CI, Wang SS.
    Transplant Proc; 2018 Nov 26; 50(9):2756-2758. PubMed ID: 30401391
    [Abstract] [Full Text] [Related]

  • 27. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE, Sanders JSF, Bemelman FJ, Betjes MGH, Burgerhof JGM, Hilbrands L, Kuypers D, van Munster BC, Nurmohamed SA, de Vries APJ, van Zuilen AD, Hesselink DA, Berger SP.
    BMC Nephrol; 2021 Jun 02; 22(1):208. PubMed ID: 34078323
    [Abstract] [Full Text] [Related]

  • 28. Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.
    Gómez-Bravo M, Prieto Castillo M, Navasa M, Sánchez-Antolín G, Lladó L, Otero A, Serrano T, Jiménez Romero C, García González M, Valdivieso A, González-Diéguez ML, de la Mata M, Pons JA, Salcedo M, Rodrigo JM, Cuervas-Mons V, González Rodríguez A, Caralt M, Pardo F, Varo Pérez E, Crespo G, Rubin Á, Guilera M, Aldea A, Santoyo J.
    Rev Esp Enferm Dig; 2022 Jun 02; 114(6):335-342. PubMed ID: 35469409
    [Abstract] [Full Text] [Related]

  • 29. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D, Molina-Andujar A, Montagud-Marrahi E, Revuelta I, Rovira J, Ventura-Aguiar P, Piñeiro GJ, De Sousa-Amorim E, Esforzado N, Cofán F, Torregrosa JV, Ugalde-Altamirano J, Ricart MJ, Centellas-Pérez FJ, Solè M, Martorell J, Ríos J, Campistol JM, Diekmann F, Oppenheimer F.
    Transplantation; 2020 Aug 02; 104(8):1686-1694. PubMed ID: 32732848
    [Abstract] [Full Text] [Related]

  • 30. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E, Citterio F, Spagnoletti G, Gargiulo A, Delreno F, Romagnoli J, Castagneto M.
    Transplant Proc; 2009 May 02; 41(4):1152-5. PubMed ID: 19460503
    [Abstract] [Full Text] [Related]

  • 31. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L, Noble J, Terrec F, Bennani HN, Chevallier E, Janbon B, Germi R, Bugnazet M, Imerzoukene F, Malvezzi P, Rostaing L, Jouve T.
    Int Urol Nephrol; 2021 Mar 02; 53(3):591-600. PubMed ID: 33058036
    [Abstract] [Full Text] [Related]

  • 32. Early Switch From Tacrolimus to Everolimus After Liver Transplantation: Outcomes at 2 Years.
    Saliba F, Duvoux C, Dharancy S, Dumortier J, Calmus Y, Gugenheim J, Kamar N, Salamé E, Neau-Cransac M, Vanlemmens C, Durand F, Pageaux G, Leroy V, Hardwigsen J, Gharbi H, Masson C, Tindel M, Conti F.
    Liver Transpl; 2019 Dec 02; 25(12):1822-1832. PubMed ID: 31631501
    [Abstract] [Full Text] [Related]

  • 33. Impact of Everolimus-based Immunosuppression on Renal Function in Liver Transplant Recipients.
    Nogueras López F, Abellan Alfocea P, Ortega Suazo EJ, López Garrido MA, Becerra Massare A, Gila Medina AM, Redondo Cerezo E, Espinosa Aguilar MD.
    Transplant Proc; 2020 Mar 02; 52(2):556-558. PubMed ID: 32035673
    [Abstract] [Full Text] [Related]

  • 34. Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results.
    Hauser IA, Marx S, Sommerer C, Suwelack B, Dragun D, Witzke O, Lehner F, Schiedel C, Porstner M, Thaiss F, Neudörfl C, Falk CS, Nashan B, Sester M.
    Eur J Immunol; 2021 Apr 02; 51(4):943-955. PubMed ID: 33306229
    [Abstract] [Full Text] [Related]

  • 35. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ.
    Kidney Int; 2017 Apr 02; 91(4):954-963. PubMed ID: 28109543
    [Abstract] [Full Text] [Related]

  • 36. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients.
    Lehmkuhl HB, Arizon J, Viganò M, Almenar L, Gerosa G, Maccherini M, Varnous S, Musumeci F, Hexham JM, Mange KC, Livi U, 2411 Study Investigators.
    Transplantation; 2009 Jul 15; 88(1):115-22. PubMed ID: 19584690
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.
    Sommerer C, Legendre C, Citterio F, Watarai Y, Oberbauer R, Basic-Jukic N, Han J, Gawai A, Bernhardt P, Chadban S.
    Transplantation; 2023 Jul 01; 107(7):1593-1604. PubMed ID: 36959121
    [Abstract] [Full Text] [Related]

  • 38. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients.
    Manzia TM, Angelico R, Toti L, Grimaldi C, Sforza D, Vella I, Tariciotti L, Lenci I, Breshanaj G, Baiocchi L, Tisone G.
    Transplant Proc; 2018 Jul 01; 50(1):175-183. PubMed ID: 29407305
    [Abstract] [Full Text] [Related]

  • 39. A 1-year randomized controlled study of everolimus versus mycophenolate mofetil with reduced-dose cyclosporine in maintenance heart transplant recipients.
    Bara C, Dengler T, Hack MA, Ladenburger S, Lehmkuhl HB.
    Transplant Proc; 2013 Jul 01; 45(6):2387-92. PubMed ID: 23953553
    [Abstract] [Full Text] [Related]

  • 40. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.